BTIG Reiterates Buy on Akebia Therapeutics, Maintains $4 Price Target

Benzinga · 2d ago
BTIG analyst Julian Harrison reiterates Akebia Therapeutics (NASDAQ:AKBA) with a Buy and maintains $4 price target.